Separate terms with OR to return results that match either term.
 
Clear All
10,000 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date (Ascending) Package Discontinuation Date Status
00409-4235-01 00409-4235 DOCETAXEL Docetaxel 20.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous June 28, 2021 In Use
00409-5068-01 00409-5068 DOCETAXEL Docetaxel 20.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous June 28, 2021 In Use
23155-0356-32 23155-0356 Palonosetron Hydrochloride Palonosetron Hydrochloride 0.05 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intravenous June 29, 2021 June 30, 2021 In Use
23155-0356-41 23155-0356 Palonosetron Hydrochloride Palonosetron Hydrochloride 0.05 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intravenous June 29, 2021 June 30, 2021 In Use
68727-0900-03 68727-0900 asparaginase erwinia chrysanthemi (recombinant)-rywn Rylaze 20.0 mg/mL Chemotherapy Miscellaneous Agent Enzyme Intramuscular June 30, 2021 In Use
68083-0401-01 68083-0401 Docetaxel Docetaxel 10.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous July 1, 2021 In Use
68083-0400-01 68083-0400 Docetaxel Docetaxel 10.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous July 1, 2021 In Use
68083-0399-01 68083-0399 Docetaxel Docetaxel 10.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous July 1, 2021 In Use
50242-0210-60 50242-0210 Pralsetinib Gavreto 100.0 mg/1 Chemotherapy Enzyme Inhibitor RET, DDR1, TRKC, FLT3, JAK1/2, TRKA, VEGFR2, PDGFRB, FGFR1 Oral July 1, 2021 In Use
50242-0210-83 50242-0210 Pralsetinib Gavreto 100.0 mg/1 Chemotherapy Enzyme Inhibitor RET, DDR1, TRKC, FLT3, JAK1/2, TRKA, VEGFR2, PDGFRB, FGFR1 Oral July 1, 2021 In Use

Found 10,000 results in 5 milliseconds — Export these results